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Background: Over the last years, the introduction of robotic technologies into Parkinson’s disease rehabilitation
settings has progressed from concept to reality. However, the benefit of robotic training remains elusive. This pilot
randomized controlled observer trial is aimed at investigating the feasibility, the effectiveness and the efficacy of
new end-effector robot training in people with mild Parkinson’s disease.
Methods: Design. Pilot randomized controlled trial.
Setting. Robot assisted gait training (EG) compared to treadmill training (CG).
Participants. Twenty cognitively intact participants with mild Parkinson’s disease and gait disturbance.
Interventions. The EG underwent a rehabilitation programme of robot assisted walking for 40 minutes, 5 times a
week for 4 weeks. The CG received a treadmill training programme for 40 minutes, 5 times a week for 4 weeks.
Main outcome measures. The outcome measure of efficacy was recorded by gait analysis laboratory. The
assessments were performed at the beginning (T0) and at the end of the treatment (T1). The main outcome was
the change in velocity. The feasibility of the intervention was assessed by recording exercise adherence and
acceptability by specific test.
Results: Robot training was feasible, acceptable, safe, and the participants completed 100% of the prescribed
training sessions. A statistically significant improvement in gait index was found in favour of the EG (T0 versus T1).
In particular, the statistical analysis of primary outcome (gait speed) using the Friedman test showed statistically
significant improvements for the EG (p = 0,0195). The statistical analysis performed by Friedman test of Step length
left (p = 0,0195) and right (p = 0,0195) and Stride length left (p = 0,0078) and right (p = 0,0195) showed a significant
statistical gain. No statistically significant improvements on the CG were found.
Conclusions: Robot training is a feasible and safe form of rehabilitative exercise for cognitively intact people with
mild PD. This original approach can contribute to increase a short time lower limb motor recovery in idiopathic PD
patients. The focus on the gait recovery is a further characteristic that makes this research relevant to clinical
practice. On the whole, the simplicity of treatment, the lack of side effects, and the positive results from patients
support the recommendation to extend the use of this treatment. Further investigation regarding the long-time
effectiveness of robot training is warranted.
Trial registration: ClinicalTrials.gov NCT01668407
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The effectiveness of non-pharmacological treatment on
gait impairment in Parkinson’s Disease (PD), such as exer-
cises [1], and physiotherapy in particular [2-4], has been
demonstrated. The goal of physiotherapy treatment aims
at enabling people with PD to maintain their maximum
level of mobility, activity and independence through moni-
toring their condition and targeting the appropriate treat-
ment [5]. Several systematic reviews and clinical studies
have shown that physical therapy can contribute to
minimize the disabling effects of motor and sensory im-
pairments, enhancing participation in societal roles and
quality of life. In the last years, electromechanical devices
such as treadmill training have also been used in PD pa-
tients. In particular, Mehrholz and colleagues have
conducted a systematic Cochrane study to assess the ef-
fectiveness and the acceptability of treadmill training in
the treatment of gait disorders for patients with PD [6].
Recently, a new Cochrane analysis showed that, in a high
number of people, there were some improvements in all
walking outcomes after physiotherapy intervention, but
these improvements were only significant for walking
speed, walking endurance and step length [5]. In the last
ten years robotic assisted devices have been used for gait
training in neurological disorder such as stroke, spinal
cord injury and multiple sclerosis, with good results on
gait recovery [7-14]. Until now only 3 studies have been
conducted to assess the effects of exoskeleton or end ef-
fector robot-assisted training in PD patients, with some
interesting preliminary results [15-17]. Our pilot random-
ized controlled trial (RCT) is aimed at investigating the
feasibility and the effects on the walking performance of
the new end-effector robotic rehabilitation locomotion
training in 10 patients with mild PD, comparing them to
10 patients with mild PD that underwent a training treat-
ment with treadmill. The purpose was to highlight the
short time modification induced by an experimental treat-
ment and to analyse the change on principal gait indexes.
Methods
Participants
This study was a pilot Randomized Controlled Trial
(RCT). We recruited idiopathic PD patients from re-
habilitation centres. They had been on stable doses of
Parkinson’s medications for at least 4 weeks prior to
study onset, and showed an endurance sufficient to keep
an upright position, assisted or unassisted, for at least
20 minutes. A preliminary medical examination included
a physical and a neurological test, and a gait analysis.
The inclusion criteria for all groups were: (a) diagnosis
of idiopathic PD by UK Brain Bank criteria, without any
other significant neurological or orthopedic problems;
(b) age between 18 and 90 years old; (c) capability to
walk, unassisted or with little assistance, for 25 feet. Thefollowing exclusion criteria were identified: (d) inability
to understand instructions required by the study (In-
formed Consent Test of Comprehension); (e) primarily
wheelchair bound; (f ) chronic and ongoing alcohol or
drug abuse, active depression, anxiety or psychosis that
might have interfered with the use of the equipment or
testing; (g) diagnosis of atypical parkinsonian syndrome;
(h) implantation of deep brain stimulation.
Procedures
After providing written informed consent, the twenty
patients were divided into two groups randomly: Expe-
rimental Group (EG) and Control Group (CG). The ran-
dom allocation to treatment was concealed and based
upon a custom computerized system, using a purpose-
built software. In order to allow a balanced subject allo-
cation into EG and CG groups, the Lehemer algorithm
was applied. Therapists were assigned to each group of
patients randomly. Blinded assessors conducted clinical




Trained professionals, who were not involved in the re-
search treatment and blind to patients’ group allocation,
performed all instrumental and clinical assessments. All
outcome assessments were collected in ON phase one
hour and half after the oral assumption of the usual dose
of levodopa. Clinical and instrumental outcomes were
performed using valid and reliable tools for PD. They
included: Hoehn and Yahr scale (HY) [18], Unified
Parkinson’s Disease Rating Scale (UPDRS) [19], and
multifactorial 3D Gait Analysis (3D-GA) (ELITE2002,
BTS, Italy).
3D Gait analysis
The 3D-Gait analysis (3D-GA) was conducted using the
following equipment: a 12-camera optoelectronic system
with passive markers (ELITE2002, BTS, Italy) to meas-
ure the kinematic of the movement; 2 force platforms
(Kistler, CH), to obtain the kinetic data of the movement
(i.e. ground reaction forces); 2 TV camera Video system
(BTS, Italy) synchronized with the optoelectronic and
force platform systems for video recording. To evaluate
the kinematics of each body segment, markers were po-
sitioned as described by Davis and colleagues [20]. Sub-
jects were asked to walk barefoot, at their own natural
pace (self-selected and comfortable speed), along a 10
meter walkway where the two force platforms were
placed. At least seven trials were collected for each sub-
ject in order to ensure the consistency of the data. All
graphs obtained from GA were normalized as % of gait
cycle, and kinetic data were normalized for individual
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ticipants involved in this study, a specific software
(Smartanalyser, BTS, Italy) enabled the calculations of
some indices (time/distance parameters, angles joint
values in specific gait cycle instant, peak values in ankle
power graph) starting from those data.
Primary and secondary outcomes
A primary outcome was the gait velocity assessed by mean
velocity (m/sec), which measured the rate of change of
position, recorded in meters per second [21]. The other
outcomes were: the cadence (step/min) that measured the
number of steps taken in a given period of time, which
was then converted into the number of steps taken per
minute [21], the step length (mm) that measured the ave-
rage distance (in meters) between two successive place-
ments of the same foot [22], the stride length (mm) that
measured the average distance (in meters) between two
successive placements of the same foot [22], the step
width (mm) that measured medio-lateral distance between
the two feet during double support, the stance time
(% stride) that measured the duration of the stance phase,
the swing time (% stride) that measured the duration of
the swing phase and the double support (% stride) that
measured the duration of double support.
Therapeutic intervention
Patients underwent a cycle of out-patients rehabilitation
treatment, consisting of at least a daily 3-hour cycle, di-
vided as follows: 45 minutes of treatment for lower limb
either with robot device or with treadmill, according to
the randomization; a treatment of occupational therapy
for the upper limb, including both dexterity and neuro-
psychological treatment, according to individually tailored
exercise scheduling. The whole therapy was performed
under the supervision of a physiotherapist.
Experimental group (EG Each subject was asked to
perform 20 sessions (5 days a week for 4 weeks) of robot
assisted gait training, using the commercially available
end effector system machines G-EO system device (Reha
Technology AG; Olten, Switzerland).
The engineering characteristic of G-EO robot is based
on end effector device with BWS and a foot plates
placed on a double crank and a rocker gear system, and
with 3 DoF each, which allows the control of the length
and the height of the steps. The foot plate angles can be
used to simulate a real over-ground high repetitive walk
[23]. The trajectories of the foot plates and the vertical
and horizontal movements of the centre of mass are
fully programmable, enabling wheelchair-bound subjects
not only for the repetitive practice of simulated floor
walking, but also to climb up and down the stairs. Heart
rate and blood pressure were monitored at the beginningand at the end of each session. During the training, the
therapist followed the treatment standing in front of the
patient, to help if necessary. The parameters of the treat-
ment were noted for each session, and the steps taken
during the simulated walking were converted into the
distance covered, based on the step length previously
chosen [24].
The practice included a robot-assisted walking therapy,
at variable speeds, for 45 minutes, with a partial body
weight support (BWS). All participants started with 30-
40% of BWS and an initial speed of 1.5 km/h; afterwards,
speed was increased to a range of 2.2 to 2.5 km/h ma-
ximum and initial BWS was decreased. After 45 minutes
the session was stopped.Control group Each subject received 20 sessions (5 days
a week for 4 weeks) of treadmill rehabilitation treatment.
All subjects were asked by the therapist to perform a
treadmill training treatment, at their best convenience,
for 45 minutes, according to a protocol setting. The
patients received video feedback to improve the gait
quality. The Gait Trainer 3, equipped with Visual Bio-
feedback Screen, provided the necessary stimulus for
retraining neural pathways, thus improving the patient’s
gait pattern and assessing the patient’s ambulation pro-
gress The biofeedback parameters could be set by the
therapist according to patient’s characteristic (i.e. impair-
ment) and to the desired goals (i.e. improvement in vel-
ocity and/or step length and/or cadence). In particular,
the patients could follow a graphical representation of
the foot, on the treadmill screen, having a visual feed-
back of their performance simultaneously.
Heart rate and blood pressure were monitored at the
beginning and at the end of each session. During the
training sessions, the therapist followed the treatment
standing on one side of the patient. The treatment pa-
rameters were noted for each session.
In both groups, subjects who did not retrieve sessions
and interrupted the treatment for more than 3 consecu-
tive days were excluded from the study.Statistical analysis
All the previously defined parameters were computed
for each participant. Mean values and standard devia-
tions of all indexes were calculated for each group. The
Kolomogorov–Smirnov tests were used to verify if the
parameters were normally distributed. As this was not
the case, we used Wilcoxon’s tests in order to detect sig-
nificant change between data at baseline (T0) and end-
point (T1). The T0 and T1 data of all patients and CG
were compared with Mann–Whitney U tests. Statistical
significance was set at p < 0.05. The Mann–Whitney test
was used to compare median scores between groups.
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This study was performed in accordance with the Dec-
laration of Helsinki and was approved by the ethics com-
mittees of IRCCS San Raffaele Pisana. Informed consent
was obtained from all subjects enrolled in this study.
Results
We screened 68 patients, 20 of whom satisfied the inclu-
sion criteria and were randomly assigned to the groups as
follows: 10 to the robot-assisted therapy (EG), 10 to the
intensive therapy (CG) (Figure 1). The distribution of the
study subjects (N = 20) by age, gender, and main clinical
and demographical characteristics did not show significant
difference between the EG and the CG (Table 1). Within
each group, no dropouts were recorded during the treat-
ment and all subjects fulfilled the protocol (compliant
subjects: N = 20). The Mann–Whitney test showed no
statistical significant differences at T0 between the two
groups for age, height, weight, mean velocity, cadence,
step width, step length, stride length, stance time, swing
time, double support, stride time. Table 2 summarizes the
observed mean ± standard deviation and the p value for all
tests (T0 versus T1), as measured on the compliant sub-
jects at T0 (N = 20), T1 (N = 20) (Table 2). The statistical
analysis of primary outcome (gait speed), which used the
Friedman test, showed statistically significant improve-
ments for the EG (p = 0,0195). The statistical ana-
lysis performed by Friedman test of Step length left
(p = 0,0195) and right (p = 0,0195) and Stride length left
(p = 0,0078) and right (p = 0,0195) showed a significant
statistical gain. No change in stance and swing time phase
left and right in EG were found. No statistically significant
improvements on the CG were found. The inter-groupAssessed for e
Analysed  EG (n=10)
Excluded from analysis (give reasons) (n=0)
Allocated to intervention EG (n=10)
Received allocated intervention (n=10) 






Figure 1 CONSORT 2010 flow diagram.statistical analysis of the gain of all parameter did not
show statistically significant improvements.
Discussion
The management of PD has been traditionally centred
on drug therapy, with levodopa seen as the “gold stan-
dard” treatment. However, there has been recently an in-
creasing support for the inclusion of rehabilitation
therapies as an adjuvant to pharmacological and neuro-
surgical treatment [25,26]. Furthermore, the guidelines
published by the National Collaborating Centre for
Chronic Conditions recommended that physiotherapy
be made available throughout all stages of the disease,
raising the profile of the profession. Walking ability,
though important for quality of life and participation in
social and economic living, can be adversely affected by
neurological disorders such as PD, spinal cord injury,
stroke or traumatic brain injury. The ability to walk
safely and independently at an acceptable speed, and
therefore regaining a level of functional gait [27], is an
important factor which enables patients to lead an au-
tonomous and self-determined life. Various studies
concerning the functional evaluation of subjects with PD
are present in literature, but evidences concerning the
outcomes of the quantitative gain, after treatments, are
very little. The measurement of temporal and spatial fea-
tures of gait is essential for the assessment of gait abnor-
malities and the quantitative evaluation of treatment
outcomes [27]. Many studies about different neuro-
logical diseases showed that the robotic devices have
been developed to relieve physical therapists of the
strenuous and unergonomical burden of treadmill BWS
(Body Weight Support) training [7-29]. For gait training,ligibility (n=68)
Excluded  (n=48)
Not meeting inclusion criteria (n=48)
Declined to participate (n=0)
Other reasons (n=0)
Allocated to intervention CG (n=10) 
Received allocated intervention (n=10)
Did not receive allocated intervention (give 
reasons) (n=0)
Analysed CG (n=10)  




Table 1 Distribution of the study participants by age,
gender, height, disease duration and other clinical
characteristics
Experimental-group Control-group
Subjects (M/F) 10 (6/4) 10 (5/5)
Height (m) 1.59 ±0.10 1.60 ±0.12
Age (years) 70.27 ±9.81 68.42 ± 9.41
Disease duration
(years)
8.41 ±4.99 8.72 ±4.74
Hoehn & Yahr
stage (range)
2.5 – 3.5 2.5 - 3.5
T0 session T1 session T0 session T1 session
UPDRS III score 53.57 ±14.74 40.45 ± 7.88
p = 0.0027
56.17 ±13.86 40.25 ±8.21
p = 0.0055
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over-ground gait, and with the correct proprioceptive
and exteroceptive feedback, is of great importance. The
first study about a robotic rehabilitation in PD patients
was conducted by Lo and colleagues with a Lokomat
robot, an exoskeleton device [15]. Lo and colleagues
gave evidence that 4 individuals with Parkinson’s disease
and symptoms of Frezing Of Gait (FOG), who received
ten 30-minute sessions of exoskeleton robot-assisted gait
training (Lokomat), showed a reduction in FOG both by
self-report and clinician-rated scoring upon completion
of training. Improvements were also observed in gait ve-
locity, stride length, and coordination, although without
statistical significance. Our study, which was conducted
with an end-effector device, confirmed this work with a
good statistical significance. The second recent studyTable 2 Results of observed means ± Standard Deviation (SD)
significant P value of Control Group (CG), Experimental Grou
CG-group
Mean S.D Mean S.D. P v
TO T1
Mean velocity [m/sec] 0,5711 0,3068 0,7022 0,2721 0,10
Cadence [step/min] 88,67 12,81 93,11 17,87 0,19
Step width [mm] 175,6 21,28 185,6 25,06 0,18
Step length [mm] DX 402,2 137,6 427,8 127,6 0,74
Step length [mm] SX 372,2 122 441,1 82,68 0,0
Stride length [mm] DX 867,8 326,6 953,3 218,5 0,57
Stride length [mm] SX 860 302,5 946,7 215,2 0,42
Stance time [% stride] DX 63,11 5,395 64,83 4,886 0,30
Swing time [% stride] DX 36,94 5,294 35,17 4,886 0,28
Stance time [% stride] SX 66,89 2,804 64,31 2,592 0,08
Swing time [% stride] SX 33,26 2,788 35,69 2,592 0,12
Double supp. [% stride] DX 15,41 4,127 14,7 3,685
Double supp. [% stride] SX 15,58 3,662 14,72 3,73
* indicate statistically significant results.was performed by Picelli and colleagues [16]. Forty-one
PD patients, randomly assigned to a robot-assisted gait
training (RT) or physiotherapy (PT), showed a statisti-
cally significant improvement in favour of the robot
therapy group performed by a Gait Trainer GT1 [16]. In
this study, the authors compared the robot therapy with
a standard physiotherapy. Studies of the effectiveness of
treadmill training, to treat gait disturbance in people
with Parkinson’s disease, have produced promising re-
sults compared with other physiotherapy approaches
[29]. Our study is the first one that compares the robot
with a treadmill device. In particular, our study was
performed by the G-EO robot, an end-effector device
designed explicitly to guide repetitive, rhythmic, bilateral
lower extremity movements. This type of intense stereo-
typed somatosensory cueing and stimulation could help
the functional recovery of the gait automatism and
speed. At the beginning of the treatment, our patients
exhibited a shorter step length, lower walking velocity
and cadence, and larger step width, if compared to nor-
mal subjects, but the robot training helped individuals to
obtain a good recovery of gait in term of mean velocity,
step length and stride length. The same gain were also
obtained with a treadmill PD training, but our sample
does not show a significant statistical gain. The stance
and swing phases did not show a change and the values
at T0 were similar to those of a normal subject. In this
pilot study, robot training produced a statistical im-
provement in term of walking capacity, walking speed
and walking consistency, in accordance with thorough
studies which have shown improvements in these mea-
sures following treadmill training [6]. One of theof gait analysis spatio-temporal parameters and
p (EG) and Normal subject Group (NG) at T0 and T1
EX-group NG-group
alue Mean S.D Mean S.D. P value
TO T1
16 0,58 0,1679 0,7644 0,202 0,0195* 1.2 ±0.01
53 98,89 10,29 105,3 9,421 NS 113.8 ±4.3
75 131,8 29,38 134,9 15,85 NS 115.5 ± 25.9
22 337,9 89,76 405 82,92 0,0195*
391* 373,7 103,7 448,4 114,4 0,0195*
03 694,8 195,8 892,2 239,1 0,0078*
58 714,6 187,7 853,7 186,5 0,0195*
08 63,22 3,193 63,33 3,969 NS 58 - 61
91 36,89 3,219 36,67 3,969 NS
2 64 3,873 61,44 4,475 NS 57 - 61
89 36,11 3,919 38,56 4,475 NS
14,44 4,851 13,33 5,099
12,22 2,167 12,22 4,265
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robot but, on the other side, the robot is easy to use and
needs one operator only for both the preparation of the
patient and during its use. On the other hand, the tread-
mill device is currently present in various rehabilitative
centres and it is normally used to treat PD patients with
some improvement [30]. Our preliminary results, though,
showed how this robot made an important gain, in gait re-
covery, with an important patient’s safety. The gain pro-
duct with our end-effector robot is in accordance with a
recent meta-analysis performed by Mehrholz, that ana-
lyses the walking recovery after cerebrovascular disease.
The results of this analysis highlighted that the recovery
may depend on the types of the training devices (end ef-
fector or exoskeleton) and, although there is an absence
of a direct empirical comparison with electromechanical-
assisted gait training devices, the meta-analysis results
showed a superior effect in support of end-effectors
treatment [9].
Conclusions
The statistical improvement in a low number of people
treated with robot device was also very interesting. In
order to better investigate the result of this type of task-
specific exercise training on gait kinetics and kinematics,
any future study should include a larger number of sub-
jects, as well as identifying underlying central and per-
ipheral neuromuscular mechanisms with a long term
follow-up.
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